<!DOCTYPE html>
<html lang="en">
<head>
  <title>RWEC Lab</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link href="https://bootswatch.com/5/spacelab/bootstrap.min.css" rel="stylesheet">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.1/font/bootstrap-icons.css">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jpswalsh/academicons@1/css/academicons.min.css">
  <!-- JavaScript -->
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js/bootstrap.bundle.min.js"></script>
  <link href="css/tyles.css" rel="stylesheet" type="text/css">
</head>

  
<body>

<!-- Blue Navigation Bar -->
<nav class="navbar navbar-expand-md navbar-light bg-light justify-content-center">
  <div class="container">
    <a class="navbar-brand" href="index.html">Real World Evidence Lab</a>
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#collapsibleNavbar">
      <span class="navbar-toggler-icon"></span>
    </button>
    <div class="collapse navbar-collapse" id="collapsibleNavbar">
      <ul class="navbar-nav">
	    <li class="nav-item">
          <a class="nav-link" href="#">Projects</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="#">Team</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="publications.html">Publications</a>
        </li>
	    <li class="nav-item">
          <a class="nav-link" href="publications.html#awards">Grants and Awards</a>
        </li>
		<li class="nav-item">
          <a class="nav-link" href="index.html#contact">Contact</a>
        </li>
      </ul>
     </div>
  </div>
</nav>
 

	 
 <div class="container">
	 <div class="row p-5">
		<p><h2>Publications</h2></p>
		<p><h5>
		Please check out my complete list of publications on <a href="https://pubmed.ncbi.nlm.nih.gov/?term=(douros%20a%5BAuthor%5D)%20NOT%20response%20%5BTitle%5D%20NOT%20flavonoids%20%5BTitle%5D%20NOT%20infants%20%5BTitle%5D%20NOT%20erratum%5BTitle%5D%20NOT%20Re%3A%5BTitle%5D%20NOT%2036027118&sort=pubdate">PubMed</a>. To date, my research has resulted in 75 peer-reviewed publications (35 as first author, 13 as senior author). Several of these publications have appeared in top-tier journals including the British Medical Journal (4), Annals of Internal Medicine, European Heart Journal, Journal of the American College of Cardiology, Diabetes Care (7), Alzheimerâ€™s & Dementia, JACC: Heart Failure, and Neurology. Moreover, my publications have been the subject of 10 editorials. Below are a few highlights of my published work.
		</p><h5>
	 </div>

	 <div class="row p-5">
	 <h3>Most significant contributions</h3>
	 </div>

	 <div class="row p-5">
		 <div class="col-md-6 p-3">
			 <img class="img-fluid float-start" src="/img/image004.jpg" alt="image004"></div>
		 <div class="col-md-6 p-3">
			 <p><b>Real-world effects of direct oral anticoagulants</b></p>
			In the past years, I studied the use of direct oral anticoagulants (DOACs) in various populations 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/28984052">https://pubmed.ncbi.nlm.nih.gov/28984052</a> & 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/34409636/">https://pubmed.ncbi.nlm.nih.gov/34409636</a> and assessed important safety issues such as their risk of liver injury 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/29519351/">https://pubmed.ncbi.nlm.nih.gov/29519351/</a>, esophageal disorders 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/32377758/">https://pubmed.ncbi.nlm.nih.gov/32377758/</a>, and bleeding when used together with antiplatelets 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/30691551/">https://pubmed.ncbi.nlm.nih.gov/30691551/</a> & 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/35036824">https://pubmed.ncbi.nlm.nih.gov/35036824/</a>. 
			 Finally, I assessed their effectiveness and safety in high-risk populations such as older adults 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/36150513/">https://pubmed.ncbi.nlm.nih.gov/36150513/</a> and patients with cancer related thrombosis 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/33836492/">https://pubmed.ncbi.nlm.nih.gov/33836492/</a>. 
			 Currently, I am studying their effectiveness and safety in patients with atrial fibrillation and liver disease, in a project funded by CIHR. 
			 Moreover, I am studying the safety of drug-drug interactions involving DOACs with my trainees Fabian and Jenny.
		 </div>
	 </div>

	 <div class="row p-5">
		 <div class="col-md-6 p-3"><img class="img-fluid float-start" src="/img/image005.png" alt="image005"></div>
		 <div class="col-md-6 p-3">
		 <p><b>Safety of sulfonylureas</b></p>			 
			 Given the use of sulfonylureas at different stages of type 2 diabetes, I assessed their safety both as first-line 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/28864502/">https://pubmed.ncbi.nlm.nih.gov/28864502/</a> and second-line treatments 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/30021781/">https://pubmed.ncbi.nlm.nih.gov/30021781/</a>. 
			 I also specifically assessed the safety of glimepiride, a sulfonylurea commonly used as active comparator in randomized trials assessing the effects of newer antidiabetic drugs 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/31596043/">https://pubmed.ncbi.nlm.nih.gov/31596043/</a>. 
			 Recently, several studies funded by CIHR and led by my trainee Jenny focused on the risk of severe hypoglycemia due to concomitant use of sulfonylureas and other medications 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/35984011">https://pubmed.ncbi.nlm.nih.gov/35984011</a> & 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/36525638">https://pubmed.ncbi.nlm.nih.gov/36525638</a> & 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/37326010">https://pubmed.ncbi.nlm.nih.gov/37326010</a>.
		 </div>
	 </div>

	 <div class="row p-5">
		 <div class="col-md-6 p-3"><img class="img-fluid float-start" src="/img/image006.jpg" alt="image006"></div>
		 <div class="col-md-6 p-3">
		 <p><b>Safety of sodium-glucose co-transporter 2 inhibitors</b></p>
			 In 2020, I was selected to lead an international, multicenter study conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), 
			 one of the largest pharmacoepidemiologic networks in the world. The study investigated the risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 (SGLT2) 
			 inhibitors, an important safety concern according to several regulatory agencies. 
			 We observed an almost 3- fold increased risk of diabetic ketoacidosis associated with SGLT2 inhibitors 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/32716707/">https://pubmed.ncbi.nlm.nih.gov/32716707/</a>. 
			 Outside of CNODES, I have also studies their risk of venous thromboembolism 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/33316246">https://pubmed.ncbi.nlm.nih.gov/33316246/</a> and the safety of their interaction with statins 
			 <a href="https://pubmed.ncbi.nlm.nih.gov/36912450/">https://pubmed.ncbi.nlm.nih.gov/36912450/</a>.
		 </div>
	 </div>
 </div>

 

 
 </body></html>
